2021
- Use of Actigraphy (Wearable Digital Sensors to Monitor Activity) in Heart Failure Randomized Clinical Trials: A Scoping Review
- Promoting Diversity in Clinical Trial Leadership: A Call to Action
- Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19
- Approaches to the Treatment of Heart Failure in an Era of Multiple Therapies – Statement From the HF Collaboratory
- Putting the “Optimal” in Optimal Medical Therapy
2020
- Endpoints in Heart Failure Drug Development: History and Future
- Changing U.S. Heart Failure Research Culture: Part 2—Recognizing Frontline Investigators and Coordinators
- Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel
- Heart Failure Collaboratory Statement on Clinical Trials on the Landscape of COVID-19
- Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation
- Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium (HF-ARC)
- Challenges and Potential Improvements to Patient Access to Pharmaceuticals
- Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials
- Barriers to Clinical Trial Efficiency and Patient Access
2019
- Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus
- Design of a “Lean” Case Report Form for Heart Failure Therapeutic Development
2018